ID: h-92a69aa3
Hypothesis
USP14 Inhibition to Accelerate Proteasomal Degradation of Synaptic Substrates
USP14 Inhibition to Accelerate Proteasomal Degradation of Synaptic Substrates.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 5 support✗ 6 oppose
🧪 Overview
USP14 Inhibition to Accelerate Proteasomal Degradation of Synaptic Substrates
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["USP14 Deubiquitinase<br/>19S Regulatory Cap Binding"]
B["Polyubiquitin Chain Trimming<br/>Substrate Premature Release"]
C["Proteasome Gating<br/>Reduced Throughput and Stalling"]
D["Tau and TDP-43 Accumulation<br/>Proteostasis Collapse"]
E["IU1 / IU1-47 Inhibitor<br/>USP14 Pharmacological Block"]
F["Enhanced Proteasomal Flux<br/>Synaptic Substrate Clearance"]
A --> B
B --> C
C --> D
E -.->|"inhibits"| A
E --> F
F -.->|"reduces"| D
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#1b5e20,stroke:#81c784,color:#81c784
style F fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix5 supports6 contradicts
Supports
USP14 inhibition enhances proteasome activity and reduces polyglutamine aggregation
Supports
Proteasome subunits show reduced activity in AD hippocampus with accumulation of ubiquitinated proteins
Supports
IU1 derivatives penetrate blood-brain barrier and reduce protein aggregates in mouse models
Supports
DUBs are considered more druggable than transcription factors with defined active sites
Contradicts
VLX1570 DUB inhibitor reached Phase 1/2 and was terminated due to toxicity (cardiac/vascular)
Contradicts
USP14 knockout mice develop sensorineural defects indicating essential functions
Contradicts
USP14 performs quality control editing of ubiquitin chains - complete inhibition eliminates checkpoint
Contradicts
Proteasome 'bounce-back' response triggers compensatory downregulation after pharmacologic activation
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — USP14
No curated PDB or AlphaFold mapping for USP14 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for USP14 (ubiquitin-specific peptidase 14) from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for USP14 (ubiquitin-specific peptidase 14).
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0087
Events (7d)
1
Price History
▲2.9%💾 Resource Usage
LLM Tokens
39,448
$0.1183
Total Cost
$0.1183
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF USP14 is knocked down via siRNA transfection in neuronal cell lines (e.g., SH-SY5Y) for 72 hours, THEN proteasome-dependent degradation of ubiquitinated synaptic proteins will increase by ≥40% comp | Increased rate of synaptic protein degradation (≥40% acceleration) following USP14 knockdown | — no observation — | pending | 0.55 |
| IF cultured primary neurons are treated with the selective USP14 inhibitor IU1 (50 μM) for 24 hours, THEN levels of synaptic substrate proteins (e.g., GluA1, PSD-95, synapsin) will decrease by ≥25% co | Decreased synaptic protein abundance (≥25% reduction) following USP14 inhibition | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF cultured primary neurons are treated with the selective USP14 inhibitor IU1 (50 μM) for 24 hours, THEN levels of synaptic substrate proteins (e.g., GluA1, PSD-95, synapsin) will decrease by ≥25% compared to vehicle-treated controls as measured by quantitative western blot.
Predicted outcome: Decreased synaptic protein abundance (≥25% reduction) following USP14 inhibition
Falsification: Synaptic protein levels show <10% change or increase after IU1 treatment, indicating USP14 inhibition does not accelerate degradation of these substrates
pendingconf 55%
IF USP14 is knocked down via siRNA transfection in neuronal cell lines (e.g., SH-SY5Y) for 72 hours, THEN proteasome-dependent degradation of ubiquitinated synaptic proteins will increase by ≥40% compared to non-targeting siRNA controls, as measured by cycloheximide chase assay.
Predicted outcome: Increased rate of synaptic protein degradation (≥40% acceleration) following USP14 knockdown
Falsification: Protein half-life measurements show <15% change after USP14 knockdown, or proteasome inhibition (with bortezomib) does not block the observed effect, indicating USP14 is not primarily regulating prote
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.